

# Anthony Gonçalves

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1230736/publications.pdf>

Version: 2024-02-01

80  
papers

5,704  
citations

236925

25  
h-index

79698

73  
g-index

100  
all docs

100  
docs citations

100  
times ranked

8214  
citing authors

#	ARTICLE	IF	CITATIONS
1	Talazoparib in Patients with Advanced Breast Cancer and a Germline <i>BRCA</i> Mutation. <i>New England Journal of Medicine</i> , 2018, 379, 753-763.	27.0	1,472
2	Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial. <i>Lancet Oncology</i> , The, 2015, 16, 1324-1334.	10.7	897
3	Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study. <i>Lancet Oncology</i> , The, 2013, 14, 64-71.	10.7	622
4	Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: a multicentre, prospective trial (SAFIRO1/UNICANCER). <i>Lancet Oncology</i> , The, 2014, 15, 267-274.	10.7	351
5	Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2021, 22, 499-511.	10.7	260
6	Time trends of overall survival among metastatic breast cancer patients in the real-life ESME cohort. <i>European Journal of Cancer</i> , 2018, 96, 17-24.	2.8	211
7	PD-1/PD-L1 Targeting in Breast Cancer: The First Clinical Evidences Are Emerging. A Literature Review. <i>Cancers</i> , 2019, 11, 1033.	3.7	160
8	Impact of breast cancer molecular subtypes on the incidence, kinetics and prognosis of central nervous system metastases in a large multicentre real-life cohort. <i>British Journal of Cancer</i> , 2019, 121, 991-1000.	6.4	113
9	Immunotherapy in Breast Cancer: the Emerging Role of PD-1 and PD-L1. <i>Current Oncology Reports</i> , 2017, 19, 64.	4.0	106
10	Efficacy of Circulating Tumor Cell Count-Driven vs Clinician-Driven First-line Therapy Choice in Hormone Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer. <i>JAMA Oncology</i> , 2021, 7, 34.	7.1	92
11	Durvalumab compared to maintenance chemotherapy in metastatic breast cancer: the randomized phase II SAFIRO2-BREAST IMMUNO trial. <i>Nature Medicine</i> , 2021, 27, 250-255.	30.7	85
12	Comparative genomic analysis of primary tumors and metastases in breast cancer. <i>Oncotarget</i> , 2016, 7, 27208-27219.	1.8	69
13	Poly(ADP-ribose) polymerase-1 mRNA expression in human breast cancer: a meta-analysis. <i>Breast Cancer Research and Treatment</i> , 2011, 127, 273-281.	2.5	66
14	The ErbB2 Signaling Network as a Target for Breast Cancer Therapy. <i>Journal of Mammary Gland Biology and Neoplasia</i> , 2006, 11, 13-25.	2.7	65
15	Talazoparib in Patients with a Germline <i>BRCA</i> -Mutated Advanced Breast Cancer: Detailed Safety Analyses from the Phase III EMBRACA Trial. <i>Oncologist</i> , 2020, 25, e439-e450.	3.7	61
16	IMpassion132 Phase III trial: atezolizumab and chemotherapy in early relapsing metastatic triple-negative breast cancer. <i>Future Oncology</i> , 2019, 15, 1951-1961.	2.4	58
17	PIKHER2: A phase IB study evaluating buparlisib in combination with lapatinib in trastuzumab-resistant HER2-positive advanced breast cancer. <i>European Journal of Cancer</i> , 2017, 86, 28-36.	2.8	48
18	Survival Impact of Locoregional Treatment of the Primary Tumor in De Novo Metastatic Breast Cancers in a Large Multicentric Cohort Study: A Propensity Score-Matched Analysis. <i>Annals of Surgical Oncology</i> , 2019, 26, 356-365.	1.5	47

#	ARTICLE	IF	CITATIONS
19	Poly(ADP-Ribose) Polymerase 1 (PARP1) Overexpression in Human Breast Cancer Stem Cells and Resistance to Olaparib. PLoS ONE, 2014, 9, e104302.	2.5	43
20	Overexpression of the Promigratory and Prometastatic PTK7 Receptor Is Associated with an Adverse Clinical Outcome in Colorectal Cancer. PLoS ONE, 2015, 10, e0123768.	2.5	43
21	Targeting BRCA Deficiency in Breast Cancer: What are the Clinical Evidences and the Next Perspectives?. Cancers, 2018, 10, 506.	3.7	40
22	MMP2 and MMP9 serum levels are associated with favorable outcome in patients with inflammatory breast cancer treated with bevacizumab-based neoadjuvant chemotherapy in the BEVERLY-2 study. Oncotarget, 2016, 7, 18531-18540.	1.8	38
23	Multimodal liquid biopsy for early monitoring and outcome prediction of chemotherapy in metastatic breast cancer. Npj Breast Cancer, 2021, 7, 115.	5.2	33
24	Real-life activity of eribulin mesylate among metastatic breast cancer patients in the multicenter national observational ESME program. International Journal of Cancer, 2019, 145, 3359-3369.	5.1	29
25	PARP Inhibitors in the Treatment of Early Breast Cancer: The Step Beyond?. Cancers, 2020, 12, 1378.	3.7	29
26	Peritumoural vascular invasion: A major determinant of triple-negative breast cancer outcome. European Journal of Cancer, 2011, 47, 1537-1545.	2.8	26
27	A Comparison of DNA Mutation and Copy Number Profiles of Primary Breast Cancers and Paired Brain Metastases for Identifying Clinically Relevant Genetic Alterations in Brain Metastases. Cancers, 2019, 11, 665.	3.7	25
28	Impact of age at diagnosis of metastatic breast cancer on overall survival in the real-life ESME metastatic breast cancer cohort. Breast, 2020, 52, 50-57.	2.2	25
29	New Therapeutics in HER2-Positive Advanced Breast Cancer: Towards a Change in Clinical Practices?. Cancers, 2020, 12, 1573.	3.7	25
30	Prospective high-throughput genome profiling of advanced cancers: results of the PERMED-01 clinical trial. Genome Medicine, 2021, 13, 87.	8.2	24
31	Immune landscape of inflammatory breast cancer suggests vulnerability to immune checkpoint inhibitors. Oncoimmunology, 2021, 10, 1929724.	4.6	22
32	Outpatient Cancer Care Delivery in the Context of E-Oncology: A French Perspective on "Cancer outside the Hospital Walls". Cancers, 2019, 11, 219.	3.7	21
33	Higher antitumor activity of trabectedin in germline BRCA2 carriers with advanced breast cancer as compared to BRCA1 carriers: A subset analysis of a dedicated phase II trial. Breast, 2017, 34, 18-23.	2.2	20
34	Adjuvant chemotherapy in lobular carcinoma of the breast: a clinicopathological score identifies high-risk patient with survival benefit. Breast Cancer Research and Treatment, 2019, 175, 379-387.	2.5	20
35	Adjuvant chemotherapy for small, lymph node-negative, triple-negative breast cancer: A single-center study and a meta-analysis of the published literature. Cancer, 2020, 126, 3837-3846.	4.1	20
36	Enhancing Abiraterone Acetate Efficacy in Androgen Receptor-positive Triple-negative Breast Cancer: Chk1 as a Potential Target. Clinical Cancer Research, 2019, 25, 856-867.	7.0	19

#	ARTICLE	IF	CITATIONS
37	Development of parallel reaction monitoring (PRM)-based quantitative proteomics applied to HER2-Positive breast cancer. <i>Oncotarget</i> , 2018, 9, 33762-33777.	1.8	17
38	Evaluation of the Incidence of Hematologic Malignant Neoplasms Among Breast Cancer Survivors in France. <i>JAMA Network Open</i> , 2019, 2, e187147.	5.9	17
39	Benefit of adjuvant chemotherapy with or without trastuzumab in pT1ab node-negative human epidermal growth factor receptor 2-positive breast carcinomas: results of a national multi-institutional study. <i>Breast Cancer Research and Treatment</i> , 2017, 162, 307-316.	2.5	16
40	Isolated ipsilateral local recurrence of breast cancer: predictive factors and prognostic impact. <i>Breast Cancer Research and Treatment</i> , 2019, 173, 111-122.	2.5	16
41	A phase Ib/II study of xentuzumab, an IGF-neutralising antibody, combined with exemestane and everolimus in hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer. <i>Breast Cancer Research</i> , 2021, 23, 8.	5.0	15
42	Safety, tolerability and antitumour activity of LY2780301 (p70S6K/AKT inhibitor) in combination with gemcitabine in molecularly selected patients with advanced or metastatic cancer: a phase IB dose escalation study. <i>European Journal of Cancer</i> , 2017, 83, 194-202.	2.8	14
43	Safety and efficacy of eribulin for "real-world" older patients with metastatic breast cancer. <i>Journal of Geriatric Oncology</i> , 2018, 9, 281-283.	1.0	14
44	Capecitabine after anthracycline and taxane exposure in HER2-negative metastatic breast cancer patients: response, survival and prognostic factors. <i>Anticancer Research</i> , 2011, 31, 1079-86.	1.1	14
45	Impact of lobular versus ductal histology on overall survival in metastatic breast cancer: a French retrospective multicentre cohort study. <i>European Journal of Cancer</i> , 2022, 164, 70-79.	2.8	14
46	Risk of Hematologic Malignant Neoplasms after Postoperative Treatment of Breast Cancer. <i>Cancers</i> , 2019, 11, 1463.	3.7	13
47	The use of "added benefit"™ to determine the price of new anti-cancer drugs in France, 2004-2017. <i>European Journal of Cancer</i> , 2021, 145, 11-18.	2.8	13
48	Overcoming Resistance to Anti-Nectin-4 Antibody-Drug Conjugate. <i>Molecular Cancer Therapeutics</i> , 2022, 21, 1227-1235.	4.1	13
49	Deterioration of Sexual Health in Cancer Survivors Five Years after Diagnosis: Data from the French National Prospective VICAN Survey. <i>Cancers</i> , 2020, 12, 3453.	3.7	12
50	Prognostic value of CEC count in HER2-negative metastatic breast cancer patients treated with bevacizumab and chemotherapy: a prospective validation study (UCBG COMET). <i>Angiogenesis</i> , 2020, 23, 193-202.	7.2	11
51	Safety Results and Analysis of Eribulin Efficacy according to Previous Microtubules-Inhibitors Sensitivity in the French Prospective Expanded Access Program for Heavily Pre-treated Metastatic Breast Cancer. <i>Cancer Research and Treatment</i> , 2018, 50, 1226-1237.	3.0	10
52	Risk of secondary hematologic malignancies associated with breast cancer chemotherapy and G-CSF support: A nationwide population-based cohort. <i>International Journal of Cancer</i> , 2021, 148, 375-384.	5.1	10
53	Efficacy of vemurafenib in patients (pts) with non-small cell lung cancer (NSCLC) with BRAF <sup>V600</sup> mutation.. <i>Journal of Clinical Oncology</i> , 2017, 35, 9074-9074.	1.6	10
54	PELICAN-IPC 2015-016/Oncodistinct-003: A Prospective, Multicenter, Open-Label, Randomized, Non-Comparative, Phase II Study of Pembrolizumab in Combination With Neo Adjuvant EC-Paclitaxel Regimen in HER2-Negative Inflammatory Breast Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 575978.	2.8	7

#	ARTICLE	IF	CITATIONS
55	TAKTIC: A prospective, multicentre, uncontrolled, phase IB/II study of LY2780301, a p70S6K/AKT inhibitor, in combination with weekly paclitaxel in HER2-negative advanced breast cancer patients. <i>European Journal of Cancer</i> , 2021, 159, 205-214.	2.8	7
56	METRO1: A Phase I Study of Metronomic Chemotherapy in Adults with Advanced Refractory Solid Tumors. <i>Anticancer Research</i> , 2016, 36, 293-9.	1.1	7
57	Docetaxel first-line therapy in HER2-negative advanced breast cancer: a cohort study in patients with prospectively determined HER2 status. <i>Anti-Cancer Drugs</i> , 2009, 20, 946-952.	1.4	6
58	A Tyrosine Kinase Expression Signature Predicts the Post-Operative Clinical Outcome in Triple Negative Breast Cancers. <i>Cancers</i> , 2019, 11, 1158.	3.7	6
59	VEGF-Related Germinal Polymorphisms May Identify a Subgroup of Breast Cancer Patients with Favorable Outcome under Bevacizumab-Based Therapy – A Message from COMET, a French Unicancer Multicentric Study. <i>Pharmaceuticals</i> , 2020, 13, 414.	3.8	6
60	Quantification of Immune Variables from Liquid Biopsy in Breast Cancer Patients Links CD2+ CD3+ T Cell Alterations with Lymph Node Invasion. <i>Cancers</i> , 2021, 13, 441.	3.7	6
61	Patients' satisfaction in early breast cancer treatment: Change in treatment over time and impact of HER2-targeted therapy. <i>Critical Reviews in Oncology/Hematology</i> , 2015, 94, 270-278.	4.4	5
62	Invasive ductal breast carcinoma with predominant intraductal component: Clinicopathological features and prognosis. <i>Breast</i> , 2016, 27, 8-14.	2.2	5
63	Immunohistochemical subtypes predict survival in metastatic breast cancer receiving high-dose chemotherapy with autologous haematopoietic stem cell transplantation. <i>European Journal of Cancer</i> , 2016, 57, 118-126.	2.8	5
64	Marketing Authorization Procedures for Advanced Cancer Drugs: Exploring the Views of Patients, Oncologists, Healthcare Decision Makers, and Citizens in France. <i>Medical Decision Making</i> , 2017, 37, 555-566.	2.4	5
65	Stem Cells Inhibition by Bevacizumab in Combination with Neoadjuvant Chemotherapy for Breast Cancer. <i>Journal of Clinical Medicine</i> , 2019, 8, 612.	2.4	5
66	TAKTIC: A prospective, multicenter, uncontrolled, phase IB/II study of LY2780301 (LY) in combination with weekly paclitaxel (wP) in HER2-negative locally advanced (LA) or metastatic breast cancer (MBC) patients.. <i>Journal of Clinical Oncology</i> , 2019, 37, 1091-1091.	1.6	5
67	Identification of Atypical Circulating Tumor Cells with Prognostic Value in Metastatic Breast Cancer Patients. <i>Cancers</i> , 2022, 14, 932.	3.7	5
68	Oral etoposide in heavily pre-treated metastatic breast cancer: results from the ESME cohort and comparison with other chemotherapy regimens. <i>Breast Cancer Research and Treatment</i> , 2019, 173, 397-406.	2.5	4
69	Circulating Tumor Cells and Bevacizumab Pharmacokinetics during Neoadjuvant Treatment Combining Chemotherapy and Bevacizumab for Early Breast Cancer: Ancillary Analysis of the AVASTEM Trial. <i>Cancers</i> , 2021, 13, 140.	3.7	4
70	Multimodality liquid biopsy for early monitoring and outcome prediction in first-line metastatic HER2-negative breast cancer: Final results of the prospective cohort from the French Breast Cancer InterGroup Unicancer (UCBG) – COMET study.. <i>Journal of Clinical Oncology</i> , 2019, 37, 3019-3019.	1.6	4
71	Circulating tumor DNA predicts efficacy of a dual AKT/p70S6K inhibitor (LY2780301) plus paclitaxel in metastatic breast cancer: plasma analysis of the TAKTIC phase IB/II study. <i>Molecular Oncology</i> , 2022, 16, 2057-2070.	4.6	4
72	The use of systemic therapies to prevent progression of inflammatory breast cancer: which targeted therapies to add on cytotoxic combinations?. <i>Expert Review of Anticancer Therapy</i> , 2017, 17, 593-606.	2.4	3

#	ARTICLE	IF	CITATIONS
73	Combining poly(ADP-ribose) polymerase inhibitors and immune checkpoint inhibitors in breast cancer: rationale and preliminary clinical results. <i>Current Opinion in Oncology</i> , 2020, 32, 585-593.	2.4	3
74	Bevacizumab in HER2-negative inflammatory breast cancer. <i>Oncoscience</i> , 2016, 3, 297-298.	2.2	2
75	Eribulin Efficacy on Brain Metastases in Heavily Pretreated Patients with Metastatic Breast Cancer. <i>Journal of Clinical Medicine</i> , 2021, 10, 1272.	2.4	1
76	Soluble BTN2A1 as a potential predictive biomarker of immune checkpoint inhibitor efficacy in advanced non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 9561-9561.	1.6	1
77	Advance Approval of Outpatient Chemotherapy via Phone Call Optimizes Healthcare Delivery without Compromising Patient Satisfaction with Care. <i>Cancers</i> , 2021, 13, 1337.	3.7	0
78	BrainStorm: A brain metastases research platform to tackle the challenge of central nervous system (CNS) metastases in solid tumors (Oncodistinct 006).. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS2066-TPS2066.	1.6	0
79	Express study: A trial in progress exploring the association between low level of genomic alteration and exceptional and unexpected response to targeted therapies in patients with solid tumors.. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS3159-TPS3159.	1.6	0
80	Molecular Profiles of Advanced Urological Cancers in the PERMED-01 Precision Medicine Clinical Trial. <i>Cancers</i> , 2022, 14, 2275.	3.7	0